(SOUTH SAN FRANCISCO, Calif.)Biotechnology company Cell Genesys Inc. said Thursday the Food and Drug Administration placed a partial clinical hold on an ongoing late-stage study for the GVAX prostate cancer va...READ MORE

(NEW YORK)Shares of Cell Genesys Inc. made a modest recovery Thursday, a day after the company stopped a late-stage trial of its prostate cancer vaccine GVAX. The South San Francisco company...READ MORE

(NEW YORK)Shares of Cell Genesys Inc. crashed to an all-time low Wednesday after the company stopped a clinical trial of its prostate cancer vaccine GVAX because of patient deaths.READ MORE

Among the stock activity stories for Wednesday, Aug. 27, from AP Financial News: NEW YORK (AP)--Shares of student lender SLM Corp., better known as Sallie Mae, rose Wednesday after...READ MORE

(SAN FRANCISCO)Cell Genesys Inc. said Wednesday it ended a clinical trial of its prostate cancer vaccine GVAX because patients who were treated with the vaccine were dying more frequently than th...READ MORE

(SOUTH SAN FRANCISCO, Calif.)Biotech drug developer Cell Genesys Inc. reported Friday its loss widened in the second quarter, despite a major revenue infusion from a collaboration with Takeda Pharmaceuticals.READ MORE

(NEW YORK) Cell Genesys Inc. said Tuesday that GVAX immunotherapy for prostate cancer, when used with ipilimumab, induces a cellular immune response that may be associated with a drop in pro...READ MORE